Advertisement
Advertisement

NEO

NEO logo

NeoGenomics, Inc.

7.68
USD
Sponsored
-0.26
-3.21%
Apr 10, 15:59 UTC -4
Closed
exchange

After-Market

7.76

+0.07
+0.96%

NeoGenomics, Inc. Profile

About

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Info & Links

CEO

Anthony P. Zook

Headquarters

9490 NEOGENOMICS WAY
FORT MYERS, FL 33912, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.neogenomics.com

Auditor

Deloitte & Touche LLP

Share holders

519

Employees

2,500

NeoGenomics, Inc. Statistics

Valuation Measures

Market Capitalization2

1.01B

Enterprise Value

1.19B

Enterprise Value/EBITDA(ttm)

-25.88

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.42

Price to Book(mrq)

1.23

Price to Cash(ytd)

23.70

Profitability

Gross Margin(ttm)

43.21%

Operating Margin(ttm)

-3.64%

Profit Margin(ttm)

-14.98%

Return on Equity(ttm)

-3.10%

Return on Invested Capital(ttm)

-9.02%

Return on Assets(ttm)

-1.85%

Income Statement

Revenue(ttm)

727.33M

Revenue Per Share(ttm)

5.60

Gross Profit(ttm)

314.29M

EBITDA(ttm)3

-46.06M

Net Income Available to Common(ttm)

-108.03M

Diluted EPS(ttm)

-0.84

Share Statistics

Beta (5Y Monthly)

1.72

52-Week Change

-17.54%

S&P 500 52-Week Change

26.10%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

129.81M

Dividend Yield

0.00%

Float4

127.02M

% Held by Insiders

2.40%

% Held by Institutions

98.50%

Balance Sheet

Total Cash(mrq)

159.62M

Total Cash Per Share(mrq)

1.23

Total Debt(mrq)

341.86M

Total Debt/Equity(mrq)

40.86%

Current Ratio(mrq)

4.26%

Quick Ratio(mrq)

3.94%

Book Value Per Share(mrq)

6.49

Cash Flow

Operating Cash Flow Per Share(ytd)

0.04

Free Cash Flow(ytd)

-19.71M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement